In a recent ASX announcement, we made mention of opening up a second clinical front for NOX66, that being to use it in conjunction with radiotherapy.
Our objective is to open up two Phase 1 studies of NOX66 + radiotherapy over the next 6 months. These will complement the NOX66 + chemotherapy study we have already announced in Eastern Europe, giving us a projected 3 clinical studies in operation in 2017.
The studies we have in mind are pilot studies intended to provide proof-of-concept outcomes in relatively small numbers of patients (10-15) in a short time frame. Each study will involve specific types of cancer.
It is anticipated one study will be in Australia and a second potential study at a site in Europe.
As with the chemotherapy study, the objective will be to use the NOX66 to prime the cancer cells so that they respond to the radiotherapy in a far more meaningful way. For many patients with late-stage cancer, radiotherapy often is only intended to provide short-term relief of symptoms such as pain. We are projecting that NOX66 will allow such a low dosage of radiation to go on to deliver a stronger, more meaningful clinical response.
One feature of radiotherapy studies is their relatively short duration. A course of NOX66 + radiotherapy will be 2-3 weeks, with a 2-3 month follow-up to determine clinical response. The clinical outcome being sought is complete remission of tumours in response to a palliative dose of radiotherapy intended to do little more than shrink tumours.
This will provide the opportunity for a fairly quick answer to the question of whether NOX66 is capable of providing the clinical outcome that we are predicting.
Details of both studies to be announced shortly.